Systemic activation of the calcium sensing receptor produces acute effects on vascular tone and circulatory function in uremic and normal rats: Focus on central versus peripheral control of vascular tone and blood pressure by cinacalcet

Journal of Pharmacology and Experimental Therapeutics

Volumn 323, Issue 1, 2007, Pages 217-226

  Fryer, Ryan M ^a   Segreti, Jason A ^a   Widomski, Deborah L ^a   Franklin, Pamela H ^a   Banfor, Patricia N ^a   Koch, Kristin A ^a   Nakane, Masaki ^a   Wu Wong, J Ruth ^a   Cox, Bryan F ^a   Reinhart, Glenn A ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; ANGIOTENSIN II; CALCIUM; CALCIUM SENSING RECEPTOR; CINACALCET; HEXAMETHONIUM; LISINOPRIL; MACROGOL 400; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PARATHYROID HORMONE; PHOSPHORUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; CARDIOVASCULAR EFFECT; CAROTID ARTERY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG INFUSION; DRUG MECHANISM; HEMODYNAMIC PARAMETERS; HYPERTENSION; LEG ARTERY; LOADING DRUG DOSE; MALE; MEAN ARTERIAL PRESSURE; MESENTERIC ARTERY; NEPHRECTOMY; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; RAT; UREMIA; VASCULAR RESISTANCE;

AFFERENT PATHWAYS; ANIMALS; BLOOD PRESSURE; CALCIUM; EFFERENT PATHWAYS; HEART RATE; MALE; MUSCLE TONUS; MUSCLE, SMOOTH, VASCULAR; NAPHTHALENES; PARATHYROID HORMONE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CALCIUM-SENSING; REGIONAL BLOOD FLOW; UREMIA; VASCULAR RESISTANCE;

EID: 34548818537     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.123901     Document Type: Article

References (49)

1. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, et al. (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516-1525.
2. Bogin E, Massry SG, and Harary I (1981) Effect of parathyroid hormone on rat heart cells. J Clin Invest 67:1215-1227.
3. Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J, and Hebert SC (1993) Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 366:575-580.
4. 2+ receptor and blood pressure regulation: a hypothesis. Am J Hypertens 11:1117-1123.
5. 2+-induced relaxation of isolated arteries. Hypertension 30:1431-1439.
6. Feuerstein G and Siren AL (1987) The opioid peptides. A role in hypertension. Hypertension 9:561-565.
7. Fox J, Lowe SH, Conklin RL, and Nemeth EF (1999) The calcimimetic NPS R-568 decreases plasma PTH in rats with mild and severe renal or dietary secondary hyperparathyroidism. Endocrine 10:97-103.
8. Fray JC, Park CS, and Valentine AN (1987) Calcium and the control of renin secretion. Endocr Rev 8:53-93.
9. Frazao JM, Martins P, and Coburn JW (2002) The calcimimetic agents: perspectives for treatment. Kidney Int 61 (Suppl.):149-154.
10. Goodman WG, Frazao JM, Goodkin DA, Turner SA, Liu W, and Coburn JW (2000) A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 58:436-445.
11. Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, Barri YM, Cohen RM, and Coburn JW (2002) The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13:1017-1024.
12. Hall JE and Brands MW (1992) The renin-angiotensin-aldosterone systems, in The Kidney: Physiology and Pathophysiology (Seldin DW ed) pp 1455-1503, Raven Press, Ltd., New York.
13. Haywood JR, Shaffer RA, Fastenow C, Fink GD, and Brody MJ (1981) Regional blood flow measurement with pulsed Doppler flowmeter in conscious rat. Am J Physiol 241:H273-H278.
14. 3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant 20:1370-1377.
15. Högestätt ED and Zygmunt PM (2002) Cardiovascular pharmacology of anandamide. Prostaglandins Leukot Essent Fatty Acids 66:343-351.
16. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
17. 2+-induced relaxation. J Pharmacol Exp Ther 289:245-250.
18. Jose PA, Eisner GM, and Felder RA (2002) Role of dopamine receptors in the kidney in the regulation of blood pressure. Curr Opin Nephrol Hypertens 11:87-92.
19. Jose PA, Eisner GM, and Felder RA (2003) Regulation of blood pressure by dopamine receptors. Nephron Physiol 95:19-27.
20. Joy MS, Kshirsagar AV, and Franceschini N (2004) Calcimimetics and the treatment of primary and secondary hyperparathyroidism. Ann Pharmacother 38:1871-1880.
21. Kunos G, Jarai Z, Batkai S, Goparaju SK, Ishac EJ, Liu J, Wang L, and Wagner JA (2000) Endocannabinoids as cardiovascular modulators. Chem Phys Lipids 108:159-168.
22. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, et al. (2005) Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 16:800-807.
23. Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, Blaisdell PW, Brenner RM, Turner SA, and Martin KJ (2003) The calcimimetic AMG 073 reduces parathyroid hormone and calcium X phosphorus in secondary hyperparathyroidism. Kidney Int 63:248-254.
24. 2+ for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics. J Pharmacol Sci 97:355-360.
25. Nakamura R, Watanabe TX, and Sokabe H (1981) Acute hypotensive action of parathyroid hormone-(1-34) fragments in hypertensive rats. Proc Soc Exp Biol Med 168:168-171.
26. Nakane M, Shaughnessy TK, Chin CL, Reinhart GA and Wu-Wong JR (2006) Potential role of cinacalcet in the CNS and cardiovascular systems may be mediated by its effects on transmitter receptors, ion channels and transporters. J Am Soc Nephrol 17:698A.
27. Odenwald T, Nakagawa K, Hadtstein C, Roesch F, Gohlke P, Ritz E, Schaefer F, and Schmitt CP (2006) Acute blood pressure effects and chronic hypotensive action of calcimimetics in uremic rats. J Am Soc Nephrol 17:655-662.
28. Ogata H, Ritz E, Odoni G, Amann K, and Orth SR (2003) Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol 14:959-967.
29. Ohanian J, Gatfield KM, Ward DT, and Ohanian V (2005) Evidence for a functional calcium-sensing receptor that modulates myogenic tone in rat subcutaneous small arteries. Am J Physiol Heart Circ Physiol 288:H1756-H1762.
30. Pang PK, Yang M, Oguro C, Phillips JG, and Yee JA (1980) Hypotensive actions of parathyroid hormone preparations in vertebrates. Gen Comp Endocrinol 41:135-138.
31. Polakowski JS, Segreti JA, Cox BF, Hsieh GC, Kolasa T, Moreland RB, and Brioni JD (2004) Effects of selective dopamine receptor subtype agonists on cardiac contractility and regional haemodynamics in rats. Clin Exp Pharmacol Physiol 31:837-841.
32. Rampe D, Lacerda AE, Dage RC, and Brown AM (1991) Parathyroid hormone: an endogenous modulator of cardiac calcium channels. Am J Physiol 261:H1945-H1950.
33. Reid JL, Rubin PC, and Petty MA (1984) Opioid peptides and central control of blood pressure. Clin Exp Hypertens A 6:107-120.
34. Reinhart GA (2004) Vitamin D analogs: novel therapeutic agents for cardiovascular disease? Curr Opin Investig Drugs 5:947-951.
35. Ruat M, Molliver ME, Snowman AM, and Snyder SH (1995) Calcium sensing receptor: molecular cloning in rat and localization to nerve terminals. Proc Natl Acad Sci U S A 92:3161-3165.
36. Sanders DB, Kelley T, and Larson D (2000) The role of nitric oxide synthase/nitric oxide in vascular smooth muscle control. Perfusion 15:97-104.
37. Schlüter KD and Piper HM (1998) Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res 37:34-41.
38. Silverberg SJ, Bone HG 3rd, Marriott TB, Locker FG, Thys-Jacobs S, Dziem G, Kaatz S, Sanguinetti EL, and Bilezikian JP (1997) Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N Engl J Med 337:1506-1510.
39. Skott O and Jensen BL (1993) Cellular and intrarenal control of renin secretion. Clin Sci (Lond) 84:1-10.
40. Smajilovic S, Hansen JL, Christoffersen TE, Lewin E, Sheikh SP, Terwilliger EF, Brown EM, Haunso S, and Tfelt-Hansen J (2006) Extracellular calcium sensing in rat aortic vascular smooth muscle cells. Biochem Biophys Res Commun 348:1215-1223.
41. van Zwieten PA (1996) Modulation of sympathetic outflow by centrally acting antihypertensive drugs. Cardiovasc Drugs Ther 10 (Suppl. 1):283-289.
42. van Zwieten PA, Blauw GJ, and van Brummelen P (1992) Serotonergic receptors and drugs in hypertension. Pharmacol Toxicol 70:S17-S22.
43. Wada M, Furuya Y, Sakiyama J, Kobayashi N, Miyata S, Ishii H, and Nagano N (1997) The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 100:2977-2983.
44. Wada M, Ishii H, Furuya Y, Fox J, Nemeth EF, and Nagano N (1998) NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 53:448-453.
45. Wada M, Nagano N, Furuya Y, Chin J, Nemeth EF, and Fox J (2000) Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int 57:50-58.
46. Wang R, Wu LY, Karpinski E, and Pang PK (1991) The effects of parathyroid hormone on L-type voltage-dependent calcium channel currents in vascular smooth muscle cells and ventricular myocytes are mediated by a cyclic AMP dependent mechanism. FEBS Lett 282:331-334.
47. 2+ receptor in rat arteries. Br J Pharmacol 125:1397-1404.
48. Wonneberger K, Scofield MA, and Wangemann P (2000) Evidence for a calcium-sensing receptor in the vascular smooth muscle cells of the spiral modiolar artery. J Membr Biol 175:203-212.
49. Ziegelstein RC, Xiong Y, He C, and Hu Q (2006) Expression of a functional extracellular calcium-sensing receptor in human aortic endothelial cells. Biochem Biophys Res Commun 342:153-163.